ADAM17 and retinoblastoma: While reinvestigating the expression pattern of miR-145, another miR that targets ADAM17 [74], we found its levels to be significantly decreased in WERI-Rb1 and Y79 RB cells and patient tumors, confirming the findings of a former study, reporting on downregulated miR-145 levels in RB cell lines and tissues [75].